Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

  title={Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial},
  author={Monica Bocchia and Silvia Gentili and Elisabetta Abruzzese and Albertina Fanelli and Franco Iuliano and Antonio Tabilio and Marilina Amabile and Francesco Forconi and Alessandro Gozzetti and D. Raspadori and Sergio Amadori and Francesco Lauria},
  journal={The Lancet},

Figures and Tables from this paper

Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance
The use of transcript-related vaccine enabled imatinib dose reduction and concomitant achievement of persistent molecular response, and immunotherapy with a specific p210 multipeptide vaccine is an alternative target-specific approach for CML patients who have never achieved a molecular response withImatinib.
K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
K562/GM-CSF vaccine appears to improve molecular responses in patients with chronic phase CML, including achieving complete molecular remissions, despite long durations of previous imatinib mesylate therapy.
Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
A 63-year-old woman with chronic myeloid leukemia with chronic-phase, Philadelphia-positive CML that was still detectable after complete cytogenic response 2 years after cessation of IFN-α therapy is in complete molecular response with an undetectable level of BCR–ABL1 transcript both in peripheral blood and in bone marrow.
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
BCR-ABL peptide vaccination may improve control of CML, especially in patients responding well to imatinib, and randomised trials are required to address this further.
It is shown that WT1 peptide vaccination in combination with TKI is feasible and effective in the therapy for imatinib-resistant CML.
Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
Data indicates that IFN-α treated CML patients in remission have increased numbers of NK-cells and clonal γδ+ T- cells and a unique plasma cytokine profile.
Emerging drugs in chronic myelogenous leukaemia
Additive immunotherapeutic strategies are emerging to synergise with imatinib in the elimination of molecular residual disease as well as two novel tyrosine kinase inhibitors that are producing clinical responses in different clinical settings.
Vaccination with autologous non‐irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
It is concluded that vaccination with autologous, non‐irradiated ‘leukaemic’ DC is feasible, safe and induces anti‐leukaemia T‐cell responses in some CML patients.
Chronic myeloid leukaemia


A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered and can reliably elicit measurable peptide-specific CD4 immune responses, including in patients after bone marrow transplantation, on interferon, or on imatinib mesylate.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
The cytogenetic and molecular response (CgR, MR) to imatinib in 191 patients with late chronic-phase Philadelphia-positive CML, previously treated with interferon alpha is determined, concluding that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time.
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine.
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
A tumor-specific, bcr-abl derived peptide vaccine can be safely administered to patients with chronic-phase CML and can elicit a bCr-abl peptide-specific immune response despite the presence of active disease in these patients and approximately 10(12) leukemia cells.
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed, and CML had not progressed to the accelerated or blast phases after a median follow-up of 18 months.
Is there any role left for p210-derived peptide vaccines in chronic myeloid leukemia?
The relevance of p210 peptides as tumor-associated antigens has been further confirmed by observing peptide-specific HLA restricted cytotoxic T-cells and CD4+ cells able to mediate killing of b3a2-CML cells and proliferation in the presence of b 3a2 containing cell lysates, respectively.
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
  • F. Belli, A. Testori, G. Parmiani
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
Vaccination of metastatic melanoma patients with autologous HSPPC-96 is feasible and devoid of significant toxicity, with induced clinical and tumor-specific T-cell responses in a significant minority of patients.
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
It is shown that in vitro immunization of human T cells with a 17 amino acid peptide representing the p210BCR-ABL fusion region resulted in peptide specific CD4+ T-cell lines designated P4, P6, and P7, which indicates that oncoprotein p210b3a2 can be degraded and processed for presentation by MHC class II molecules at the surface of leukemic cells.
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
The high frequency of cytotoxic T-lymphocyte responses and the occurrence of clinical tumor regressions support continued investigation of multipeptide vaccines administered with GM-CSF in adjuvant.